In a patient taking rosuvastatin 40 mg whose total cholesterol exceeds 200 mg/dL and low‑density lipoprotein cholesterol exceeds 125 mg/dL and who needs LDL‑C below 70 mg/dL, what additional medication should be added?

Add Ezetimibe to Rosuvastatin 40 mg

Yes, add ezetimibe 10 mg to the current rosuvastatin 40 mg regimen. This patient on maximally tolerated high-intensity statin therapy with LDL-C >125 mg/dL (well above the <70 mg/dL target) requires additional lipid-lowering therapy, and ezetimibe is the guideline-recommended first step before considering more expensive options.

Rationale for Ezetimibe Addition

The 2018 AHA/ACC guidelines explicitly recommend adding ezetimibe when LDL-C remains ≥70 mg/dL on maximally tolerated statin therapy in patients requiring aggressive LDL-C reduction 1. The 2024 International Lipid Expert Panel reinforces this approach, stating that if LDL levels remain above 55-70 mg/dL after 4-6 weeks on high-intensity statin, clinicians should "immediately add ezetimibe" 2.

The stepwise approach is critical:

• Rosuvastatin 40 mg is already the maximum dose (high-intensity statin)
• Current LDL-C >125 mg/dL requires ~55 mg/dL reduction to reach <70 mg/dL target
• Ezetimibe typically reduces LDL-C by an additional 20-25% when added to statin therapy 3
• This combination strategy is supported by the IMPROVE-IT trial, which demonstrated cardiovascular benefit from adding ezetimibe to statin therapy 3

Why Ezetimibe Before PCSK9 Inhibitors

Ezetimibe should be added before considering PCSK9 inhibitors for several compelling reasons 1:

• Cost-effectiveness: Ezetimibe is widely available as a generic medication, making it dramatically more affordable than PCSK9 inhibitors
• Proven safety profile: Ezetimibe has extensive long-term safety data and excellent tolerability 4
• Guideline hierarchy: Both AHA/ACC and ESC/EAS guidelines recommend ezetimibe as the second-line agent (Class IIa recommendation) before PCSK9 inhibitors 1, 5
• Practical efficacy: Simulation studies show that adding ezetimibe to statin therapy achieves LDL-C <70 mg/dL in the majority of patients, leaving only a minority requiring PCSK9 inhibitors 6

When to Consider PCSK9 Inhibitors

PCSK9 inhibitors (alirocumab, evolocumab, or inclisiran) should only be considered if 1, 3, 5:

1. LDL-C remains ≥70 mg/dL after 4-6 weeks on rosuvastatin 40 mg + ezetimibe 10 mg
2. The patient meets very high-risk criteria (multiple major ASCVD events or one major event plus multiple high-risk conditions)
3. Cost-benefit analysis is favorable (noting that long-term safety beyond 3 years remains uncertain) 4, 6

Alternative Consideration: Bempedoic Acid

If the patient is statin-intolerant or has specific contraindications, bempedoic acid could be considered as an alternative add-on therapy, though this is less commonly used as first-line add-on therapy 3, 5. However, since this patient is tolerating rosuvastatin 40 mg, ezetimibe remains the preferred choice.

Monitoring Plan

After adding ezetimibe:

• Recheck lipid panel in 4-6 weeks 2
• If LDL-C <70 mg/dL: continue current regimen with annual monitoring
• If LDL-C remains ≥70 mg/dL: reassess cardiovascular risk status and consider PCSK9 inhibitor if patient meets very high-risk criteria

Common Pitfalls to Avoid

• Don't skip ezetimibe and jump to PCSK9 inhibitors: This violates guideline recommendations and is not cost-effective 6
• Don't assume maximum statin dose alone is sufficient: Only 23.7-50.5% of adherent statin users achieve LDL-C targets with statin monotherapy 7
• Don't delay adding ezetimibe: The 2024 guidelines emphasize "immediate" addition when targets aren't met 2